{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:23:00Z","timestamp":1791559380348,"version":"4.3.4"},"reference-count":20,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2026,8,31]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>Sinonasal mucosal melanoma (SNMM) is a rare and aggressive malignancy with few effective treatments. Unlike cutaneous melanoma, responses to immune checkpoint inhibitors (ICIs) in mucosal subtypes are typically modest. We describe a case of metastatic SNMM with a remarkable and durable response to ICIs despite therapy discontinuation following multiple severe immune-related adverse events (irAEs). Remarkably, the patient remained disease-free for over a year while on prolonged immunosuppression, including high-dose steroids for Guillain-Barr\u00e9 syndrome and risankizumab for ICI-induced psoriasis and psoriatic arthritis. This case suggests the following: (1) durable remission after limited ICI exposure can occur in metastatic SNMM, (2) severe multisystem irAEs may reflect robust antitumour immunity, and (3) biologic immunosuppressants such as IL-23 blockade may effectively control refractory irAEs without apparent compromise of oncologic outcomes. These findings highlight an exceptional therapeutic trajectory and raise new questions about the biology linking irAEs, immunotherapy efficacy and long-term disease control in mucosal melanoma.<\/jats:p>","DOI":"10.1136\/bcr-2025-271708","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:15:20Z","timestamp":1790100920000},"page":"e271708","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Durable remission of sinonasal mucosal melanoma despite early ICI discontinuation and risankizumab treatment for irAEs"],"prefix":"10.1136","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2245-5586","authenticated-orcid":false,"given":"Zarina","family":"Brune","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, The Geisel School of Medicine at Dartmouth and Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The Geisel School of Medicine at Dartmouth and Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Shirai","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The Geisel School of Medicine at Dartmouth and Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"2026092211151142000_19.9.e271708.1","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2020.616174","article-title":"Mucosal Melanoma of the Head and Neck: A Retrospective Review and Current Opinion","volume":"7","author":"Pincet","year":"2020","journal-title":"Front Surg"},{"key":"2026092211151142000_19.9.e271708.2","doi-asserted-by":"crossref","DOI":"10.2217\/mmt-2018-0003","article-title":"Combatting mucosal melanoma: recent advances and future perspectives","volume":"5","author":"Tyrrell","year":"2018","journal-title":"Melanoma Manag"},{"key":"2026092211151142000_19.9.e271708.3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.680407","article-title":"Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions","volume":"12","author":"Mao","year":"2021","journal-title":"Front Immunol"},{"key":"2026092211151142000_19.9.e271708.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00083-2"},{"key":"2026092211151142000_19.9.e271708.5","first-page":"2521","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"119","author":"Robert","year":"2015","journal-title":"Br J Cancer"},{"key":"2026092211151142000_19.9.e271708.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0207-6"},{"key":"2026092211151142000_19.9.e271708.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.9258"},{"key":"2026092211151142000_19.9.e271708.8","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.annonc.2022.06.004","article-title":"Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study","volume":"33","author":"Dimitriou","year":"2022","journal-title":"Ann Oncol"},{"key":"2026092211151142000_19.9.e271708.9","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13122931","article-title":"Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis","volume":"13","author":"Dimitriou","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026092211151142000_19.9.e271708.10","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.749064","article-title":"Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis","volume":"11","author":"Bastacky","year":"2021","journal-title":"Front Oncol"},{"key":"2026092211151142000_19.9.e271708.11","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026092211151142000_19.9.e271708.12","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltac016","article-title":"Prevalence of inverse psoriasis subtype with immune checkpoint inhibitors","volume":"2","author":"Jfri","year":"2022","journal-title":"Immunother Adv"},{"key":"2026092211151142000_19.9.e271708.13","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-020-01308-2","article-title":"Activation of CD8 T cells accelerates anti-PD-1 antibody-induced psoriasis-like dermatitis through IL-6","volume":"3","author":"Tanaka","year":"2020","journal-title":"Commun Biol"},{"key":"2026092211151142000_19.9.e271708.14","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jaad.2020.08.137","article-title":"Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group","volume":"84","author":"Nikolaou","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2026092211151142000_19.9.e271708.15","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jaad.2022.02.030","article-title":"Treatment of immune checkpoint inhibitor-mediated psoriasis: A systematic review","volume":"87","author":"Said","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2026092211151142000_19.9.e271708.16","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1111\/jdv.20809","article-title":"Systemic treatment of immune checkpoint inhibitor-induced psoriasis: Inference-based guidance","volume":"39","author":"Papp","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026092211151142000_19.9.e271708.17","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/CMR.0000000000000875","article-title":"Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma","volume":"33","author":"Gargiulo","year":"2023","journal-title":"Melanoma Res"},{"key":"2026092211151142000_19.9.e271708.18","doi-asserted-by":"crossref","first-page":"1573495","DOI":"10.3389\/fimmu.2025.1573495","article-title":"Case Report: Guselkumab treatment for sintilimab-exacerbated psoriasis in a cancer patient","volume":"16","author":"Ke","year":"2025","journal-title":"Front Immunol"},{"key":"2026092211151142000_19.9.e271708.19","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1093\/ced\/llaf184","article-title":"Psoriasis vulgaris in patients with a recent history of neoplasia: safety of interleukin-23 inhibitors. A multicentre retrospective study","volume":"50","author":"Satolli","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"2026092211151142000_19.9.e271708.20","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jdcr.2021.03.029","article-title":"Nivolumab-induced psoriasis successfully treated with risankizumab-rzaa in a patient with stage III melanoma","volume":"11","author":"Glinos","year":"2021","journal-title":"JAAD Case Rep"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-271708","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:15:22Z","timestamp":1790100922000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-271708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":20,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,22]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/bcr-2025-271708"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-271708","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}